Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Diabetes (DM): early-phase trial registry

2 of 3 indexed Diabetes (DM) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Diabetes (DM): 3 US clinical trials tracked, 2 recruiting.

Diabetes (DM) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is David K Carroll, running 1 of these trials.

Enrollment posture brief

Registry condition diabetes-dm

OPEN 2 | RECR 67% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Diabetes (this)67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Diabetes (DM)

Diabetes (DM) lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetes (DM) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetes (DM) is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Named interventions

Most-linked intervention names on Diabetes (DM) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cooling stimulus starting at 30 C initial temperature Other
1 trials
Warming stimulus starting at 35 C initial temperature Other
1 trials
Warming stimulus starting at 34 C initial temperature Other
1 trials
Warming stimulus starting at 32 C initial temperature Other
1 trials
Warming stimulus starting at 30 C initial temperature Other
1 trials
Sodium Chloride 0.9% Drug
1 trials
Arginine hydrochloride Drug
1 trials
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min Drug
1 trials

US sites by state

Facility locations filed on Diabetes (DM) trials. A trial with sites in several states counts in each.

Washington 1 trials
North Carolina 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetes (DM) page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes (DM) condition card totals 3 registered trials; most-linked intervention Cooling stimulus starting at 30 C initial temperature; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.